FrancophonIA/ELRC3.0 huggingface dataset:
English: The usual recommended starting dose is one tablet of Procoralan 5 mg twice daily increasing if necessary to one tablet of Procoralan 7.5 mg twice daily.
Croatian: Uobičajena doza je jedna tableta Procoralana od 5 mg dva puta na dan, koja se, ako je potrebno, povećava na jednu tabletu Procoralana od 7,5 mg dva puta na dan.
English: In some cases (e.g. if you are elderly), your doctor may prescribe half the dose i.e., one half 5 mg tablet of Procoralan 5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet in the evening.
Croatian: U nekim slučajevima (npr. kod starijih osoba) postoji mogućnost da Vam liječnik propiše pola doze, t.j. jednu polovicu tablete Procoralan 5 mg (što odgovara količini 2,5 mg ivabradina) ujutro i jednu polovicu tablete Procoralan 5 mg uvečer.
English: Palpitations and cardiac extra beats, feeling sick (nausea), constipation, diarrhoea, abdominal pain, spinning sensation (vertigo), difficulty breathing (dyspnoea), muscle cramps, changes in laboratory parameters : high blood levels of uric acid, an excess of eosinophils (a type of white blood cell) and elevated creatinine in blood (a breakdown product of muscle), skin rash, angioedema (such as swollen face, tongue or throat, difficulty in breathing or swallowing), low blood pressure, fainting, feeling of tiredness, feeling of weakness, abnormal ECG heart tracing, double vision, impaired vision.
Croatian: Osjećaj lupanja srca i neuobičajeni otkucaji srca, osjećaj slabosti (mučnina), zatvor, proljev, bol u trbuhu, osjećaj vrtnje (vrtoglavica), poteškoće u disanju (dispneja), grčevi u mišićima i promjene u laboratorijskim pretragama: visoka razina mokraćne kiseline u krvi, prekomjeran broj eozinofila (vrsta bijelih krvnih stanica) i povišena razina kreatinina u krvi (nastaje zbog raspada mišića), kožni osip, angioedem (kao npr. oticanje lica, jezika ili grla, poteškoće u disanju ili gutanju), niski krvni tlak, gubitak svijesti, osjećaj umora, osjećaj slabosti, abnormalni nalaz EKG-a, dvoslike, oštećen vid.
English: INFORMATION IN BRAILLE PROCORALAN 7.5 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU PROCORALAN 7,5 mg
English: INFORMATION IN BRAILLE PROCORALAN 5 mg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU PROCORALAN 5 mg
English: Do not take Procoralan if you are breast-feeding (see “Do not take Procoralan”).
Croatian: Ne uzimajte Procoralan ako dojite (vidjeti “Nemojte uzimati Procoralan”).
English: MARKETING AUTHORISATION NUMBER(S) EU/1/05/316/001-007
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/05/316/001-007
English: MARKETING AUTHORISATION NUMBER(S) EU/1/05/316/008-014
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/05/316/008-014
English: Procoralan with food and drink Avoid grapefruit juice during treatment with Procoralan.
Croatian: Tijekom liječenja s Procoralanom izbjegavajte konzumiranje soka od grejpa.
English: Talk to your doctor or pharmacist before taking Procoralan - if you suffer from heart rhythm disorders (such as irregular heartbeat, palpitation, increase in chest pain) or sustained atrial fibrillation (a type of irregular heartbeat), or an abnormality of electrocardiogram (ECG) called ‘long QT syndrome', - if you have symptoms such as tiredness, dizziness or shortness of breath (this could mean that your heart is slowing down too much), - if you suffer from symptoms of atrial fibrillation (pulse rate at rest unusually high (over 110 beats per minute) or irregular, without any apparent reason, making it difficult to measure), - if you have had a recent stroke (cerebral attack), - if you suffer from mild to moderate low blood pressure, - if you suffer from uncontrolled blood pressure, especially after a change in your antihypertensive treatment, - if you suffer from severe heart failure or heart failure with abnormality of ECG called ‘bundle branch block', - if you suffer from chronic eye retinal disease, - if you suffer from moderate liver problems, - if you suffer from severe renal problems.
Croatian: - ako bolujete od poremećaja srčanog ritma (kao nepravilni rad srca, osjećaj lupanja srca, pojačan bol u prsima) ili fibrilacije atrija (vrsta nepravilnog rada srca) ili abnormalnosti u elektrokardiogramu (EKG) koje se nazivaju “sindrom dugog QT intervala”, - ako imate simptome kao što je umor, omaglica ili nedostatka zraka (to bi moglo značiti da Vam srce radi presporo), - ako imate simptome fibrilacije atrija (puls u mirovanju neuobičajeno visok (iznad 110 otkucaja u minuti) ili nepravilan, bez jasnog razloga, što otežava njegovo mjerenje), - ako ste nedavno imali moždani udar, - ako imate blago ili umjereno niski krvni tlak, - ako bolujete od visokog krvnog tlaka koji nije dobro kontroliran, osobito nakon promjene u terapiji
English: Procoralan 7.5 mg tablets are salmon-coloured, triangular, film-coated tablets engraved with “7.5” on one face and on the other.
Croatian: Procoralan 7,5 mg tablete su trokutaste filmom obložene tablete boje lososa s utisnutom oznakom “7.5” na jednoj strani , a na drugoj.
English: Servier Italia S.p.A. Tel: +39 (06) 669081
Croatian: Tel: +39 (06) 669081
English: - in clinical electrophysiology studies, ivabradine had no effect on atrioventricular or intraventricular conduction times or corrected QT intervals;
Croatian: - u kliničkim ispitivanjima elektrofiziologije, ivabradin nije imao učinka na atrioventrikulska ili na intraventrikulska vremena provođenja ili korigirane QT-intervale; - u bolesnika s disfunkcijom lijeve klijetke (istisna frakcija lijeve klijetke (LVEF) između 30 i 45%),
English: NAME OF THE MEDICINAL PRODUCT Procoralan 5 mg film-coated tablets
Croatian: NAZIV LIJEKA Procoralan 5 mg filmom obložene tablete
English: Procoralan 5 mg: one film-coated tablet contains 5 mg ivabradine (equivalent to 5.390 mg ivabradine as hydrochloride).
Croatian: Procoralan 5 mg: jedna filmom obložena tableta sadrži 5 mg ivabradina (što odgovara 5,390 mg ivabradinklorida).
English: NAME OF THE MEDICINAL PRODUCT Procoralan 7.5 mg film-coated tablets
Croatian: NAZIV LIJEKA Procoralan 7,5 mg filmom obložene tablete
English: Procoralan 7.5 mg: one film-coated tablet contains 7.5 mg ivabradine (equivalent to 8.085 mg ivabradine as hydrochloride).
Croatian: Procoralan 7,5 mg: jedna filmom obložena tableta sadrži 7,5 mg ivabradina (što odgovara 8,085 mg ivabradinklorida).
English: Make sure to tell your doctor if you are taking any of the following medicines, as a dose adjustment of Procoralan or monitoring should be required: - fluconazole (an antifungal medicine) - rifampicin (an antibiotic) - barbiturates (for difficult sleeping or epilepsy) - phenytoin (for epilepsy) - Hypericum perforatum or St John's Wort (herbal treatment for depression) - QT prolonging medicines to treat either heart rhythm disorders or other conditions : - quinidine, disopyramide, ibutilide, sotalol, amiodarone (to treat heart rhythm disorders) - bepridil (to treat angina pectoris) - certain types of medicines to treat anxiety, schizophrenia or other psychoses (such as pimozide, ziprasidone, sertindole) - anti-malarial medicines (such as mefloquine or halofantrine) - intravenous erythromycin (an antibiotic) - pentamidine (an antiparasitic medicine) - cisapride (against the gastro-oesophageal reflux) - Some types of diuretics which may cause decrease in blood potassium level, such as furosemide, hydrochlorothiazide, indapamide (used to treat oedema, high blood pressure).
Croatian: Ako uzimate neke od slijedećih lijekova, svakako o tome obavijestite svog liječnika koji bi trebao prilagoditi dozu Procoralana ili pratiti liječenje: - flukonazol (antifungik) - rifampicin (antibiotik) - barbiturati (za otežano spavanje ili epilepsiju) - fenitoin (za epilepsiju) - Hypericum perforatum ili Gospina trava (biljna terapija za depresiju) - lijekovi koji produljuju QT-interval i primjenjuju se za liječenje poremećaja srčanog ritma ili drugih bolesti:
English: What Procoralan looks like and contents of the pack Procoralan 5 mg tablets are salmon-coloured, oblong film-coated tablets scored on both sides, engraved with “5” on one face and on the other.
Croatian: Procoralan 5 mg tablete su duguljaste filmom obložene tablete boje lososa s razdjelnom crtom na obje strane, s utisnutom oznakom “5” na jednoj strani, a na drugoj.
English: josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone (see sections 4.5 and 5.2) - Combination with verapamil or diltiazem which are moderate CYP3A4 inhibitors with heart rate reducing properties (see section 4.5) - Pregnancy, lactation and women of child-bearing potential not using appropriate contraceptive measures (see section 4.6)
Croatian: Istodobna primjena s verapamilom ili diltiazemom koji su umjereni inhibitori CYP3A4 s učinkom na smanjenje srčane frekvencije (vidjeti dio 4.5) Trudnoća, dojenje i žene generativne dobi koje ne koriste prikladne mjere kontracepcije (vidjeti dio
English: NAME OF THE MEDICINAL PRODUCT Procoralan 5 mg film-coated tablets ivabradine
Croatian: Procoralan 5 mg filmom obložene tablete ivabradin
English: NAME OF THE MEDICINAL PRODUCT Procoralan 7.5 mg film-coated tablets ivabradine
Croatian: Procoralan 7,5 mg filmom obložene tablete ivabradin
English: Procoralan 5 mg film-coated tablets Procoralan 7.5 mg film-coated tablets ivabradine
Croatian: Uputa o lijeku: Informacija za bolesnika Procoralan 5 mg filmom obložene tablete Procoralan 7,5 mg filmom obložene tablete ivabradin
English: - Non cardiovascular QT prolonging medicinal products (e.g. pimozide, ziprasidone, sertindole,
Croatian: - Ostali lijekovi koji produljuju QT-interval (npr. pimozid, ziprasidon, sertindol, meflokin, halofantrin,
English: As the treatment for angina or chronic heart failure is usually life-long, you should discuss with your doctor before stopping this medicinal product.
Croatian: Ako prestanete uzimati Procoralan: Liječenje angine ili kroničnog zatajenja srca obično je doživotno.
English: EU Number
Croatian: Broj EU odobrenja Zaštićeno ime
English: The infusion should last around 15 minutes.
Croatian: Infuzija treba trajati oko 15 minuta.
English: The full EPAR for Respreeza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Respreeza nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What is Respreeza and what is it used for?
Croatian: Što je Respreeza i za što se koristi?
English: Other information about Respreeza
Croatian: Ostale informacije o lijeku Respreeza
English: What measures are being taken to ensure the safe and effective use of Respreeza?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Respreeza?
English: The recommended dose of Respreeza is 60 mg per kilogram body weight, given once a week.
Croatian: Preporučena doza lijeka Respreeza iznosi 60 mg po kilogramu tjelesne težine, a daje se jednom tjedno.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Respreeza on 20 August 2015.
Croatian: Europska komisija izdala je odobrenje za stavljanje lijeka Respreeza u promet koje vrijedi na prostoru Europske unije od 20. kolovoza 2015.
English: Allergic reactions have been observed during treatment, some of which were severe.
Croatian: Tijekom liječenja uočene su alergijske reakcije, od kojih su neke bile ozbiljne.
English: The company that markets Respreeza will carry out a further study to assess whether an increased dose of 120 mg/kg may lead to improved effects compared with the currently recommended dose.
Croatian: Tvrtka koja stavlja lijek Respreeza u promet provest će dodatno ispitivanje kako bi ocijenila može li povećana doza od 120 mg/kg rezultirati poboljšanim djelovanjem u usporedbi s trenutno preporučenom dozom.
English: The decrease in lung density after 24 months was around 2.6 g/l in patients who received Respreeza, compared with a decrease of around 4.2 g/l in patients receiving placebo.
Croatian: Smanjenje gustoće plućnog tkiva nakon 24 mjeseca iznosilo je otprilike 2,6 g/l u bolesnika koji su primili lijek Respreeza u usporedbi sa smanjenjem od otprilike 4,2 g/l u bolesnika koji su primili placebo.
English: What are the risks associated with Respreeza?
Croatian: Koji su rizici povezani s lijekom Respreeza?
English: This is a summary of the European public assessment report (EPAR) for Respreeza.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Respreeza.
English: Why is Respreeza approved?
Croatian: Zašto je lijek Respreeza odobren?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Respreeza have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Respreeza također su uključene u sažetak opisa svojstava lijeka i uputu o lijeku.
English: No other major concerns have been identified about the safety of the medicine.
Croatian: Nisu utvrđeni drugi ozbiljni razlozi za zabrinutost u pogledu sigurne primjene lijeka.
English: It is not intended to provide practical advice on how to use Respreeza.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Respreeza.
English: Therefore, the Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Respreeza's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Respreeza nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: The most common side effects with Respreeza (which may affect up to 1 in 10 people) are dizziness, headache, dyspnoea (shortness of breath) and nausea.
Croatian: Najčešće nuspojave lijeka Respreeza (mogu se javiti u do 1 na 10 osoba) su vrtoglavica glavobolja, dispneja (otežano disanje) i mučnina.
English: For more information about treatment with Respreeza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Respreeza pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Respreeza is available as a powder and solvent to be made into a solution for infusion (drip) into a vein.
Croatian: Respreeza je dostupan kao prašak i otapalo za otopinu za infuziju (drip) u venu.
English: Allergic reactions were the main safety concern with Respreeza, but advice on how to manage this risk has been included in the product information.
Croatian: Alergijske reakcije bile su glavni izvor zabrinutosti u pogledu sigurne primjene lijeka Respreeza, no savjeti o kontroli tog rizika nisu uključeni u informacije o lijeku.
English: In the study, Respreeza was compared with placebo (a dummy treatment) and the main measure of effectiveness was the decrease in lung density.
Croatian: U tom ispitivanju je lijek Respreeza uspoređen s placebom (prividnim liječenjem), a glavna mjera njegove djelotvornosti bilo je povećanje gustoće plućnog tkiva.
English: Respreeza human alpha1-proteinase inhibitor
Croatian: Respreeza ljudski inhibitor alfa1-proteinaze
English: Respreeza is used to slow down damage to the lungs in patients with severe disease.
Croatian: Respreeza se koristi za usporavanje štete prouzročene na plućima u bolesnika s teškim oblikom bolesti.
English: Because of the risk of severe allergic reactions, Respreeza must not be used in patients who are lacking IgA, a protein in the blood, and who have developed antibodies against it because these patients are more prone to allergic reactions.
Croatian: Uzimajući u obzir rizik od ozbiljnih alergijskih reakcija, Respreeza se ne smije koristiti u bolesnika kojima nedostaje bjelančevina imunoglobin tipa A (IgA) u krvi i onih koji su razvili protutijela protiv njega budući da su ti bolesnici skloniji alergijskim reakcijama.
English: Respreeza is a medicine used in adults with alpha1-proteinase inhibitor deficiency, an inherited disorder that can cause lung problems such as increasing shortness of breath and which may also affect the liver.
Croatian: Respreeza je lijek koji se koristi u odraslih osoba s deficijencijom inhibitora alfa1-proteinaze, nasljednim poremećajem koji može uzrokovati probleme s plućima poput sve većih poteškoća s disanjem koji također može utjecati i na jetru.
English: Lung density is an indicator of the extent of lung damage: the bigger the decrease in lung density, the greater is the damage to the lung.
Croatian: Gustoća plućnog tkiva pokazatelj je stupnja oštećenja pluća: što je manja gustoća plućnog tkiva, veće je oštećenje pluća.
English: For practical information about using Respreeza, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o korištenju lijeka Respreeza pročitajte u uputi o lijeku, odnosno obratite se svojem liječniku ili ljekarniku.
English: What benefits of Respreeza have been shown in studies?
Croatian: Koje su koristi lijeka Respreeza utvrđene u ispitivanjima?
English: The active substance in Respreeza, human alpha1-proteinase inhibitor, is a natural protein in the blood which protects lung tissue from damage.
Croatian: Djelatna tvar lijeka Respreeza, ljudski inhibitor alfa1-proteinaze, prirodna je bjelančevina u krvi koja štiti plućno tkivo od oštećenja.
English: The first infusion should be given under the supervision of a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.
Croatian: Prva se infuzija treba primijeniti pod nadzorom zdravstvenog radnika s iskustvom u liječenju deficijencije alfa1-proteinaze.
English: The main study with Respreeza showed that the medicine is effective at slowing down the damage to the lungs in patients with alpha1-proteinase inhibitor deficiency, and this effect is considered relevant for patients with severe disease.
Croatian: Glavno ispitivanje provedeno s lijekom Respreeza pokazalo je da je lijek djelotvoran u usporavanju oštećenja pluća u bolesnika s deficijencijom inhibitora alfa1-proteinaze, te se ovo djelovanje smatra relevantnim za bolesnike s teškim oblikom bolesti.
English: How is Respreeza used?
Croatian: Kako djeluje Respreeza?
English: Subsequent infusions can be given by a caregiver or by the patient.
Croatian: Pružatelj skrbi ili bolesnik mogu kasnije sami primjenjivati infuzije.
English: Respreeza has been shown to slow down lung damage in one main study involving 180 patients with lung damage due to alpha1-proteinase inhibitor deficiency.
Croatian: Dokazano je da lijek Respreeza usporava oštećenje pluća u jednom glavnom ispitivanju koje je obuhvatilo 180 bolesnika s oštećenjem pluća uslijed deficijencije inhibitora alfa1-proteinaze.
English: Respreeza contains the active substance human alpha1-proteinase inhibitor.
Croatian: Respreeza sadrži djelatnu tvar ljudski inhibitor alfa1-proteinaze.
English: It is obtained from human blood and works by replacing the protein that is lacking in patients with alpha1-proteinase inhibitor deficiency.
Croatian: Prikuplja se iz ljudske krvi i djeluje kao zamjena za bjelančevinu koja nedostaje bolesnicima s deficijencijom inhibitora alfa1-proteinaze.
English: For the full list of all side effects and restrictions with Respreeza, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja zabilježenih pri primjeni lijeka Respreeza potražite u uputi o lijeku.
English: How does Respreeza work?
Croatian: Kako se Respreeza koristi?
English: ATCvet code: QI04AA02.
Croatian: ATCvet kod: QI04AA02.
English: Date of first authorisation:09/01/2019
Croatian: Datum prvog odobrenja: 09/01/2019
English: *Below the level of detection by the validated RT-PCR method at 1.32 log10 TCID50/ml
Croatian: *Ispod razine detekcije što je provjereno metodom RT-PCR pri 1,32 log10 TCID50/ml
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Croatian: Detaljne informacije o ovom veterinarsko-medicinskom proizvodu dostupne su na internetskoj stranici Europske agencije za lijekove http://www.ema.europa.eu/.
English: People with known hypersensitivity to aluminium hydroxide, thiomersal or saponins should avoid contact with the veterinary medicinal product.
Croatian: Osobe s poznatom preosjetljivošću na aluminijev hidroksid, tiomersal ili saponine trebaju izbjegavati kontakt s ovim veterinarsko-medicinskim proizvodom.
English: Each ml contains:
Croatian: Jedan ml sadržava:
English: Adjuvants: Aluminium hydroxide (Al
Croatian: Adjuvansi: Aluminijev hidroksid (Al
English: The development of local reactions is very common at the site of injection after vaccination.
Croatian: Razvijanje lokalnih reakcija vrlo je česta nuspojava na mjestu primjene injekcije nakon cijepljenja.
English: EXP {month/year} Once broached use within 10 hours.
Croatian: Jednom otvorenu upotrijebiti unutar 10 sati.
English: The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
Croatian: Nositelj odobrenja za stavljanje u promet mora obavijestiti Europsku komisiju o planovima za stavljanje u promet VMP-a koji je odobren ovom odlukom.
English: The use of this veterinary medicinal product is only allowed under the particular conditions established by European Community legislation on the control of bluetongue.
Croatian: Uporaba ovog veterinarsko-medicinskog proizvoda dopuštena je samo pod određenim uvjetima utvrđenim zakonodavstvom Europske zajednice o kontroli bolesti plavog jezika.
English: The level of efficacy for other species may differ from that observed in sheep and cattle.
Croatian: Razina djelotvornosti za druge vrste može biti drugačija od one opažene u ovaca i goveda.
English: In this category of animals the vaccine should be used only according to the benefit/risk assessment by the responsible veterinarian and/or National Competent Authorities on the current vaccination policies against Bluetongue Virus (BTV).
Croatian: U ovoj kategoriji životinja cjepivo treba primjenjivati samo u skladu s procjenom odnosa koristi/rizika koju provedu odgovorni veterinar i/ili nacionalna nadležna tijela u pogledu trenutačnih pravila o cijepljenu protiv bolesti virusa plavog jezika (BTV).
English: Inactivated bluetongue virus (BTV)
Croatian: Inaktivirani virus bolesti plavog jezika (BTV)
English: The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Croatian: SPC-a su ili dozvoljene tvari za koje je u tablici 1., Priloga Uredbi Komisije (EU) br. 37/2010 navedeno da određivanje MRL-a nije nužno ili se smatra da nisu obuhvaćene Uredbom (EZ) br. 470/2009 kada se primjenjuju kao u ovom veterinarsko medicinskom proizvodu.
English: A transient increase in rectal temperature, not exceeding 2.3 °C, during the 48 hours following vaccination, is very common.
Croatian: Prolazno povećanje rektalne temperature, od najviše 2,3 °C, tijekom 48 sati nakon cijepljenja vrlo je često.
English: If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Croatian: Ako zamijetite bilo koju nuspojavu, čak i one koje nisu navedene u ovoj uputi o VMP-u ili smatrate da veterinarsko-medicinski proizvod ne djeluje, obavijestite svojeg veterinara.